Groups/days
Treatment/Dose (mg/mL) |
Intervals |
| Zero time |
7 |
14 |
21 |
28 |
| Normal Control |
223.4
± 4.07 |
230.5
± 5.11 |
234.9
± 2.75 |
242.4
± 5.60 |
251
± 4.33 |
| Control + CAMBA (25mg/kg) |
215.9
± 5.64 |
221.86
± 4.58 |
228.16
± 6.80 |
234.25
± 4.07 |
239.66
± 7.62 |
| Control +CAMBA (50mg/kg) |
219.68
± 4.73 |
224.19
± 6.05 |
229.33
± 5.17 |
238.48
± 4.95 |
240.32
± 2.44 |
| Diabetic Control |
210.25
± 3.78 |
195.49
± 5.36* |
190.82
± 7.08* |
185.55
± 4.15* |
179.50
± 6.04* |
| Diabetic + CAMBA (25mg/kg) |
213.59
± 2.26 |
216.60
± 3.57** |
219.40
± 4.05** |
222.00
± 6.23** |
225.83
± 4.15** |
| Diabetic +CAMBA (50mg/kg) |
216.30
± 2.94 |
221.5
± 4.22** |
226.05
± 3.66** |
229.14
± 5.02** |
234.40
± 6.18** |
| Diabetic +Glibenclamide(5mg/kg) |
214.15
± 6.43 |
218.09
± 4.72** |
220.93
± 6.40** |
223.69
± 4.55** |
226.35
± 5.20** |
Values are given as mean ± SD for groups of eight animals each. Values are statistically significant at *P<0.01. Diabetic control rats were compared with normal control rats.
Experimental groups were compared with diabetic control